[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 164 pages | ID: ABA6613B38B8EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Drugs In Development, 2022, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 9, 21, 4, 23, 3 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris - Overview
Acne Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acne Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acne Vulgaris - Companies Involved in Therapeutics Development
Acne Vulgaris - Drug Profiles
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
Mar 25, 2022: Sun Pharma presents phase 3 data for WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris at the AAD Annual Meeting
Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States
Jan 24, 2022: Kintor Pharmaceutical : Voluntary announcement dosing of first patient for acne vulgaris phase II clinical trial of KX-826 in China
Jan 24, 2022: Kintor Pharma Announced successful dosing of the first patient for acne vulgaris phase II clinical trial of KX-826
Jan 14, 2022: Ascletis doses first participant in Phase II acne oral therapy trial
Dec 17, 2021: Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris
Nov 01, 2021: Sun Pharma announces availability of WINLEVI (clascoterone) cream 1% in the U.S. for topical treatment of acne vulgaris
Oct 05, 2021: VYNE Therapeutics Announces its China partner’s enrollment of first patient in phase 3 study of AMZEEQ in patients with moderate to severe acne
Sep 13, 2021: Voluntary announcement Adapalene Clindamycin Hydrochloride combination gel passing the on site inspection for drug registration in China becoming the third GMP inspection that the company has passed this year
Aug 08, 2021: China NMPA approves Phase II clinical trial of ASC40 for the treatment of patients with Acne
Jul 28, 2021: Kintor Pharmaceutical announces dosing of first batch of subjects in phase I clinical trial of GT20029 in China
Jul 19, 2021: VYNE announces initiation of investigator initiated trial evaluating AMZEEQ (minocycline) with oral isotretinoin in patients with moderate to severe acne
Jul 13, 2021: Hoth Therapeutics announces positive confirmatory results from in vivo model of HT-003 assets as potential treatment against acne
Jul 13, 2021: Kintor Pharmaceutical receives IND clearance by the U.S. FDA for GT20029 to treat androgenetic alopecia and acne
Jun 01, 2021: Almirall receives FDA approval to produce Seysara (sarecycline) at the Sant Andreu de la Barca (Barcelona) plant
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acne Vulgaris, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acne Vulgaris - Pipeline by Akaal Pharma Pty Ltd, 2022
Acne Vulgaris - Pipeline by AMD Therapeutics LLC, 2022
Acne Vulgaris - Pipeline by Amgen Inc, 2022
Acne Vulgaris - Pipeline by Amytrx Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Acne Vulgaris - Pipeline by AOBiome LLC, 2022
Acne Vulgaris - Pipeline by Arcutis Biotherapeutics Inc, 2022
Acne Vulgaris - Pipeline by Atacama Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Attillaps Holdings Inc, 2022
Acne Vulgaris - Pipeline by Avecho Biotechnology Ltd, 2022
Acne Vulgaris - Pipeline by Avicanna Inc, 2022
Acne Vulgaris - Pipeline by Bausch Health Companies Inc, 2022
Acne Vulgaris - Pipeline by Biofrontera AG, 2022
Acne Vulgaris - Pipeline by Biozeus Pharmaceutical SA, 2022
Acne Vulgaris - Pipeline by Blueberry Therapeutics Ltd, 2022
Acne Vulgaris - Pipeline by Boston Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Botanix Pharmaceuticals Ltd, 2022
Acne Vulgaris - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2022
Acne Vulgaris - Pipeline by Claritas Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
Acne Vulgaris - Pipeline by Cosmo Pharmaceuticals NV, 2022
Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, 2022
Acne Vulgaris - Pipeline by Dermata Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Dermavant Sciences Inc, 2022
Acne Vulgaris - Pipeline by Devonian Health Group Inc, 2022
Acne Vulgaris - Pipeline by Eligo Bioscience SA, 2022
Acne Vulgaris - Pipeline by Galephar Pharmaceutical Research Inc, 2022
Acne Vulgaris - Pipeline by Hoth Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Journey Medical Corp, 2022
Acne Vulgaris - Pipeline by Kintor Pharmaceutical Ltd, 2022
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
Acne Vulgaris - Pipeline by Lipidio Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Lipidor AB, 2022
Acne Vulgaris - Pipeline by Madam Therapeutics BV, 2022
Acne Vulgaris - Pipeline by Maruho Co Ltd, 2022
Acne Vulgaris - Pipeline by Matrisys Bioscience Inc, 2022
Acne Vulgaris - Pipeline by Mayne Pharma Group Ltd, 2022
Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Novabiotics Ltd, 2022
Acne Vulgaris - Pipeline by Novan Inc, 2022
Acne Vulgaris - Pipeline by Novartis AG, 2022
Acne Vulgaris - Pipeline by Ortho Dermatologics Inc, 2022
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Phagelux Inc, 2022
Acne Vulgaris - Pipeline by PHI Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Promius Pharma LLC, 2022
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Revive Therapeutics Ltd, 2022
Acne Vulgaris - Pipeline by Riptide Bioscience Inc, 2022
Acne Vulgaris - Pipeline by Sagimet Biosciences Inc, 2022
Acne Vulgaris - Pipeline by Sanofi, 2022
Acne Vulgaris - Pipeline by SaNOtize Research and Development Corp, 2022
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Acne Vulgaris - Pipeline by Timber Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Verge Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by VYNE Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Vyome Therapeutics Inc, 2022
Acne Vulgaris - Dormant Projects, 2022
Acne Vulgaris - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Acne Vulgaris, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications